about
Creating a data exchange strategy for radiotherapy research: towards federated databases and anonymised public datasetsCT-based delineation of lymph node levels and related CTVs in the node-negative neck: DAHANCA, EORTC, GORTEC, NCIC,RTOG consensus guidelines.The need for radiotherapy in Europe in 2020: Not only data but also a cancer plan.Has the outlook improved for amifostine as a clinical radioprotector?Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6 and 7 randomised controlled trial.Chemical radioprotection: a critical review of amifostine as a cytoprotector in radiotherapy.Detection of hypoxic cells in a C3H mouse mammary carcinoma using the comet assayAdaptive management of cervical cancer radiotherapy.Virtual reality in radiation therapy training.Imaging of normal lung, liver and parotid gland function for radiotherapy.FDG-PET/CT for detection of the unknown primary head and neck tumor.Delineation of the neck node levels for head and neck tumors: a 2013 update. DAHANCA, EORTC, HKNPCSG, NCIC CTG, NCRI, RTOG, TROG consensus guidelines.HERO (Health Economics in Radiation Oncology): a pan-European project on radiotherapy resources and needs.Cost calculation: a necessary step towards widespread adoption of advanced radiotherapy technology.Guidelines for equipment and staffing of radiotherapy facilities in the European countries: final results of the ESTRO-HERO survey.A longitudinal study of follow-up activities after curative treatment for head and neck cancer.CT-based delineation of organs at risk in the head and neck region: DAHANCA, EORTC, GORTEC, HKNPCSG, NCIC CTG, NCRI, NRG Oncology and TROG consensus guidelines.Failure pattern and salvage treatment after radical treatment of head and neck cancer.How many new cancer patients in Europe will require radiotherapy by 2025? An ESTRO-HERO analysis.Vitiligo patients experience barriers in accessing care.Cost evaluations of radiotherapy: What do we know? An ESTRO-HERO analysis.Glutamatergic stimulation induces GluN2B translation by the nitric oxide-Heme-Regulated eIF2α kinase in cortical neurons.Post-mastectomy radiotherapy in Denmark: from 2D to 3D treatment planning guidelines of The Danish Breast Cancer Cooperative Group.Aggravation of dyspnea in stage I non-small cell lung cancer patients following stereotactic body radiotherapy: Is there a dose-volume dependency?Fear of cancer recurrence and unmet needs among breast cancer survivors in the first five years. A cross-sectional study.Loss of lung function after chemo-radiotherapy for NSCLC measured by perfusion SPECT/CT: Correlation with radiation dose and clinical morbidity.Sino-nasal cancer in Denmark 1982-1991--a nationwide survey.The impact of cancer incidence and stage on optimal utilization of radiotherapy: Methodology of a population based analysis by the ESTRO-HERO project.The optimal utilization proportion of external beam radiotherapy in European countries: An ESTRO-HERO analysis.IAEA-HypoX. A randomized multicenter study of the hypoxic radiosensitizer nimorazole concomitant with accelerated radiotherapy in head and neck squamous cell carcinoma.Cytotoxic effect of misonidazole and cyclophosphamide on aerobic and hypoxic cells in a C3H mammary carcinoma in vivoProphylactic Swallowing Exercises in Head and Neck Cancer Radiotherapy.Time-resolved dose distributions to moving targets during volumetric modulated arc therapy with and without dynamic MLC tracking.Five versus six fractions of radiotherapy per week for squamous-cell carcinoma of the head and neck (IAEA-ACC study): a randomised, multicentre trial.[Global adherence project to disease-modifying therapies in patients with relapsing multiple sclerosis: 2-year interim results].Biology-guided adaptive radiation therapy - presence or future?Aspiration pneumonia in patients treated with radiotherapy for head and neck cancer.Factors associated with acute and late dysphagia in the DAHANCA 6 & 7 randomized trial with accelerated radiotherapy for head and neck cancer.Radiotherapy staffing in the European countries: final results from the ESTRO-HERO survey.The value of routine follow-up after treatment for head and neck cancer. A national survey from DAHANCA.
P50
Q26864472-282D11EB-BD3C-424E-AA6C-B044F01302D8Q30336279-84E11E24-8AB8-4C07-B34D-9D477BD0E08DQ30982764-68A5FEF5-C243-474D-8AA1-8116F4E5039EQ34071798-41A31028-6833-4E32-A068-93333403D468Q34265391-7A2A42A0-7CF5-4840-BADC-31B9C0C0D4F4Q35042100-078E2E5F-8767-40E3-83F8-099614FD0DD7Q36431067-C3EE56CE-0B31-4944-AA98-FA60D1895BF2Q37706797-8B5E2053-F595-4754-8E8D-CB4AB024B069Q37781195-0D220533-EDB6-494D-99CB-E2704F0AFA5CQ37787277-E91B02E7-7163-4F66-AF4E-510F5E18C113Q37948480-E025EB9F-E847-4CE1-B010-6A7CF58E4365Q38159027-2C76E7D3-E3E2-439B-8420-759342E4FB61Q38281665-0E1726AA-1618-45EA-A227-23E9303508DFQ38388288-DCD19D43-FC3A-4DD2-92B5-03F7AB11B8E9Q38394790-70E5BADB-968A-48B4-843B-9BD475E46817Q38439769-CD7F65A3-8956-4796-ABA1-38208C833252Q38567611-632D5433-70A8-4777-A491-828757230FFAQ38798521-04A71EEC-F17E-4811-ACA8-2CBBA2AAD0CBQ38902506-D7391C1B-2874-48F7-87D1-4491288B31B9Q39014619-32B1AA55-ACDB-43E4-AD01-4003C687E71EQ39050786-EA7EC3CA-C544-4877-82CA-E550CFCB309CQ39457267-9A8044E1-44DD-46AE-91F7-BE42FBBCBE77Q40094265-05FBA3B3-F3F4-4559-9EDE-433B8263FE77Q40287365-FC8EFF8F-325A-4A4B-B097-DF5F68772C27Q40378733-2628FB92-9388-4B48-B6F5-233C25CE9191Q40704394-6F10AAC9-7FCE-4260-B10C-448CA6AB8285Q40711433-265A2E95-4EAD-4489-8EC1-C244294A3357Q40909843-B4015A53-17D8-4E08-A536-6DDD97301B66Q40932803-C95AD869-664F-42FB-BD7D-74DCB2236A3DQ41013490-F463978D-C544-4D29-82B2-E3FBE2492C40Q41203286-D7DAECC8-C94E-49DE-B986-CABDC8C6F7B5Q41410758-9E8B0CBD-C8A4-466D-8B89-4CC934BA91DEQ42182824-A2CA7E0F-9D31-4A1E-8562-53D2F6B6B128Q42656104-3175FFE3-62D8-41B3-B1AD-7FED0BCAA28BQ42851401-BC96ECF5-FA8D-4D9D-8E78-7FED59AB8A23Q42910927-65D1D7DA-E117-4100-8B85-F8092AD01DF8Q43529865-5005A329-2886-43EC-AD02-B4CBF9D26AA7Q43572761-504E7BFB-3D5B-4020-BF5F-18A4E0BAAC2EQ43658397-A0354254-97DC-494F-8565-8C12C53C8081Q43721929-FFF0665A-3CCF-452E-B9B7-AA62BCFD535A
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Cai Grau
@ast
Cai Grau
@en
Cai Grau
@es
Cai Grau
@nl
Cai Grau
@sl
type
label
Cai Grau
@ast
Cai Grau
@en
Cai Grau
@es
Cai Grau
@nl
Cai Grau
@sl
prefLabel
Cai Grau
@ast
Cai Grau
@en
Cai Grau
@es
Cai Grau
@nl
Cai Grau
@sl
P1053
I-8161-2014
P106
P31
P3829
P496
0000-0003-3548-3527